<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2176-6223</journal-id>
<journal-title><![CDATA[Revista Pan-Amazônica de Saúde]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Pan-Amaz Saude]]></abbrev-journal-title>
<issn>2176-6223</issn>
<publisher>
<publisher-name><![CDATA[Instituto Evandro Chagas. Secretaria de Vigilância em Saúde e Ambiente. Ministério da Saúde]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2176-62232013000200006</article-id>
<article-id pub-id-type="doi">10.5123/S2176-62232013000200006</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Imunoexpressão de TNF-&#945; e TGF-&#946; em lesões de pacientes nas diversas formas clínicas da hanseníase por meio da técnica de imunoistoquímica]]></article-title>
<article-title xml:lang="en"><![CDATA[Immunolabeling of TNF-&#945; and TGF-&#946; in lesions of patients in several clinical forms of leprosy by immunohistochemistry]]></article-title>
<article-title xml:lang="es"><![CDATA[Inmunoexpresión de TNF-&#945; y TGF-&#946; en lesiones de pacientes en las diversas formas clínicas de la hanseniasis a través de técnica de inmunohistoquímica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[Jorge Rodrigues de]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Paulo Ygor Agrassar da]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[Luis Paulo Miranda Araújo]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aarão]]></surname>
<given-names><![CDATA[Tinara Leila de Souza]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[Denise da Silva]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fuzii]]></surname>
<given-names><![CDATA[Hellen Thais]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quaresma]]></surname>
<given-names><![CDATA[Juarez Antônio Simões]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidade Federal do Pará Núcleo de Medicina Tropical ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidade do Estado do Pará Núcleo de Medicina Tropical ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2013</year>
</pub-date>
<volume>4</volume>
<numero>2</numero>
<fpage>45</fpage>
<lpage>53</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S2176-62232013000200006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S2176-62232013000200006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S2176-62232013000200006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Visando compreender melhor a dinâmica da hanseníase envolvendo a participação da resposta imunológica em pacientes, foi analisada, pela técnica de imunoistoquímica, a imunomarcação do fator de necrose tumoral alfa (TNF-&#945;) e do fator de crescimento e transformação beta (TGF-&#946;) nas diversas formas clínicas da doença. Para a realização do estudo, foram selecionadas 50 biópsias de pacientes distribuídos de acordo com o diagnóstico definido a partir da análise histopatológica, conforme a classificação de Madri. Dentre as quatro formas clínicas estudadas, a análise atribuída aos polos de resistência tuberculoide e de suscetibilidade lepromatoso a partir da citocina TNF-&#945; denotou um aumento nos níveis de expressão da proteína na forma tuberculoide da doença. Referente à imunoexpressão do TGF-&#946;, a distribuição analítica entre as quatro formas clínicas apresentou significância estatística dentre os grupos estudados. Sobre as formas polares da doença, a diferença entre os grupos demonstrou que a participação do TGF-&#946; foi maior na forma lepromatosa da doença. No estudo paramétrico envolvendo a análise das variáveis estudadas, todas as formas clínicas apresentaram correlação negativa envolvendo o crescimento linear de ambas as citocinas. A partir dos achados, o presente estudo conclui que, durante a evolução espectral da doença, a atuação de ambas as citocinas é fundamental para o controle da resposta imunológica perante o bacilo, reforçando a necessidade de elaboração de estudos que complementem a participação dessas moléculas diante da fisiopatogenia da doença.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Aiming at better understanding leprosy dynamics, involving immune response in patients, the immunolabeling of tumor necrosis factor alpha (TNF-&#945;) and transforming growth factor beta (TGF-&#946;) was analyzed by immunohistochemistry in several clinical forms of the disease. In the investigation, 50 biopsies were selected from patients distributed according to the diagnosis determined by histopathological analysis, as Madrid classification. Among the four clinical forms studied, the analysis of the poles of tuberculoid resistance and lepromatous susceptibility by cytokine TNF-&#945; showed an increase in the levels of protein expression in tuberculoid form. Regarding the immunolabeling of TGF-&#946;, the analytical distribution between the four clinical forms presented statistical significance among the groups studied. In the polar forms of disease, the difference between the two groups showed higher TGF-&#946; level in lepromatous form. In the parametric study, involving the analysis of variables studied, all clinical forms showed negative correlation in the linear growth of both cytokines. This study concludes that, during the spectral evolution of the disease, both cytokines action is essential to control the immune response before the bacillus, and the necessity of doing studies that complement how these molecules participate in the physiopathogeny of the disease.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Con el objetivo de comprender mejor la dinámica de la hanseniasis, abarcando la participación de la respuesta inmunológica en pacientes, fue analizada, por la técnica de inmunohistoquímica, la inmunomarcación del factor de necrosis tumoral alfa (TNF-&#945;) y del factor de crecimiento y transformación beta (TGF-&#946;) en las diversas formas clínicas de la enfermedad. Para realizar el estudio, se seleccionaron 50 biopsias de pacientes distribuidos de acuerdo al diagnóstico definido a partir del análisis histopatológico, según la clasificación de Madrid. Entre las cuatro formas clínicas estudiadas, el análisis atribuido a los polos de resistencia tuberculoide y de susceptibilidad lepromatosa a partir de la citocina TNF-&#945; indicó un aumento en los niveles de expresión de la proteína de forma tuberculoide de la enfermedad. Referente a la inmunoexpresión del TGF-&#946;, la distribución analítica entre las cuatro formas clínicas presentó significado estadístico entre los grupos estudiados. Sobre las formas polares de la enfermedad, la diferencia entre los grupos demostró que la participación del TGF-&#946; fue superior en la forma lepromatosa de la enfermedad. En el estudio paramétrico abarcando el análisis de las variables estudiadas, todas las formas clínicas presentaron correlación negativa comprendiendo el crecimiento linear de ambas citocinas. A partir de esos hallazgos, el presente estudio concluye que, durante la evolución espectral de la enfermedad, la actuación de ambas citocinas es fundamental para el control de la respuesta inmunitaria delante del bacilo, reforzando la necesidad de elaborar estudios que complementen la participación de esas moléculas frente a la fisiopatogenia de la enfermedad.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Hanseníase]]></kwd>
<kwd lng="pt"><![CDATA[Imunoistoquímica]]></kwd>
<kwd lng="pt"><![CDATA[Fator de Necrose Tumoral alfa]]></kwd>
<kwd lng="pt"><![CDATA[Fator de Crescimento Transformador beta]]></kwd>
<kwd lng="en"><![CDATA[Leprosy]]></kwd>
<kwd lng="en"><![CDATA[Immunohistochemistry]]></kwd>
<kwd lng="en"><![CDATA[Tumor Necrosis Factor-alpha]]></kwd>
<kwd lng="en"><![CDATA[Transforming Growth Factor beta]]></kwd>
<kwd lng="es"><![CDATA[Lepra]]></kwd>
<kwd lng="es"><![CDATA[Inmunohistoquímica]]></kwd>
<kwd lng="es"><![CDATA[Factor de Necrosis Tumoral alfa]]></kwd>
<kwd lng="es"><![CDATA[Factor de Crecimiento Transformador beta]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana"><b>ARTIGO ORIGINAL | ORIGINAL ARTICLE | ART&Iacute;CULO ORIGINAL</b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="4"><b><a name="topo"></a>Imunoexpress&#227;o de TNF-&#945; e TGF-&#946; em les&#245;es de pacientes nas diversas formas cl&#237;nicas da hansen&#237;ase por meio da t&#233;cnica de imunoistoqu&#237;mica</b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>Immunolabeling of TNF-&#945; and TGF-</b></font><font size="3"><b><font face="Verdana">&#946; in lesions of patients in several clinical forms of leprosy by immunohistochemistry</font></b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>Inmunoexpresi&#243;n de TNF-&#945; y TGF-</b></font><font size="3"><b><font face="Verdana">&#946;</font></b></font><font face="Verdana" size="3"><b> en lesiones de pacientes en las diversas formas cl&#237;nicas de la hanseniasis a trav&#233;s de t&#233;cnica de inmunohistoqu&#237;mica</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Jorge Rodrigues de Sousa<sup>I</sup>; Paulo Ygor Agrassar da Silva<sup>II</sup>; Luis Paulo Miranda Ara&#250;jo Soares<sup>II</sup>; Tinara Leila de Souza Aar&#227;o<sup>I</sup>; Denise da Silva Pinto<sup>I</sup>; Hellen Thais Fuzii<sup>I</sup>; Juarez Ant&#244;nio Sim&#245;es Quaresma</b></font><font face="Verdana" size="2"><b><sup>I</sup></b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><sup>I</sup><i>Laborat&#243;rio de Imunopatologia, N&#250;cleo de Medicina Tropical, Universidade Federal do Par&#225;, Bel&#233;m, Par&#225;, Brasil</i></font>    <br> <font face="Verdana" size="2"><sup>II</sup><i>Laborat&#243;rio de Imunopatologia, N&#250;cleo de Medicina Tropical, Universidade do Estado do Par&#225;, Bel&#233;m, Par&#225;, Brasil</i></font></p>     <p><font size="2" face="Verdana"><a href="#endereco">Endere&ccedil;o para correspond&ecirc;ncia    <br> Correspondence    <br> Direcci&oacute;n para correspondencia</a></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade>     <p><font face="Verdana" size="2"><b>RESUMO</b></font></p>     <p><font face="Verdana" size="2">Visando compreender melhor a din&#226;mica da hansen&#237;ase envolvendo a participa&#231;&#227;o da resposta imunol&#243;gica em pacientes, foi analisada, pela t&#233;cnica de imunoistoqu&#237;mica, a imunomarca&#231;&#227;o do fator de necrose tumoral alfa (TNF-&#945;) e do fator de crescimento e transforma&#231;&#227;o beta (TGF-&#946;) nas diversas formas cl&#237;nicas da doen&#231;a. Para a realiza&#231;&#227;o do estudo, foram selecionadas 50 bi&#243;psias de pacientes distribu&#237;dos de acordo com o diagn&#243;stico definido a partir da an&#225;lise histopatol&#243;gica, conforme a classifica&#231;&#227;o de Madri. Dentre as quatro formas cl&#237;nicas estudadas, a an&#225;lise atribu&#237;da aos polos de resist&#234;ncia tuberculoide e de suscetibilidade lepromatoso a partir da citocina TNF-&#945; denotou um aumento nos n&#237;veis de express&#227;o da prote&#237;na na forma tuberculoide da doen&#231;a. Referente &#224; imunoexpress&#227;o do TGF-&#946;, a distribui&#231;&#227;o anal&#237;tica entre as quatro formas cl&#237;nicas apresentou signific&#226;ncia estat&#237;stica dentre os grupos estudados. Sobre as formas polares da doen&#231;a, a diferen&#231;a entre os grupos demonstrou que a participa&#231;&#227;o do TGF-&#946; foi maior na forma lepromatosa da doen&#231;a. No estudo param&#233;trico envolvendo a an&#225;lise das vari&#225;veis estudadas, todas as formas cl&#237;nicas apresentaram correla&#231;&#227;o negativa envolvendo o crescimento linear de ambas as citocinas. A partir dos achados, o presente estudo conclui que, durante a evolu&#231;&#227;o espectral da doen&#231;a, a atua&#231;&#227;o de ambas as citocinas &#233; fundamental para o controle da resposta imunol&#243;gica perante o bacilo, refor&#231;ando a necessidade de elabora&#231;&#227;o de estudos que complementem a participa&#231;&#227;o dessas mol&#233;culas diante da fisiopatogenia da doen&#231;a.</font></p>     <p><font face="Verdana" size="2"><b>Palavras-chave: </b>Hansen&#237;ase; Imunoistoqu&#237;mica; Fator de Necrose Tumoral alfa; Fator de Crescimento Transformador beta.</font></p> <hr size="1" noshade>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><b>ABSTRACT</b></font></p>     <p><font face="Verdana" size="2">Aiming at better understanding leprosy dynamics, involving immune response in patients, the immunolabeling of tumor necrosis factor alpha (TNF-&#945;) and transforming growth factor beta (TGF-&#946;) was analyzed by immunohistochemistry in several clinical forms of the disease. In the investigation, 50 biopsies were selected from patients distributed according to the diagnosis determined by histopathological analysis, as Madrid classification. Among the four clinical forms studied, the analysis of the poles of tuberculoid resistance and lepromatous susceptibility by cytokine TNF-&#945; showed an increase in the levels of protein expression in tuberculoid form. Regarding the immunolabeling of TGF-&#946;, the analytical distribution between the four clinical forms presented statistical significance among the groups studied. In the polar forms of disease, the difference between the two groups showed higher TGF-&#946; level in lepromatous form. In the parametric study, involving the analysis of variables studied, all clinical forms showed negative correlation in the linear growth of both cytokines. This study concludes that, during the spectral evolution of the disease, both cytokines action is essential to control the immune response before the bacillus, and the necessity of doing studies that complement how these molecules participate in the physiopathogeny of the disease.</font></p>     <p><font face="Verdana" size="2"><b>Keywords: </b>Leprosy; Immunohistochemistry; Tumor Necrosis Factor-alpha; Transforming Growth Factor beta.</font></p> <hr size="1" noshade>     <p><font face="Verdana" size="2"><b>RESUMEN</b></font></p>     <p><font face="Verdana" size="2">Con el objetivo de comprender mejor la din&#225;mica de la hanseniasis, abarcando la participaci&#243;n de la respuesta inmunol&#243;gica en pacientes, fue analizada, por la t&#233;cnica de inmunohistoqu&#237;mica, la inmunomarcaci&#243;n del factor de necrosis tumoral alfa (TNF-&#945;) y del factor de crecimiento y transformaci&#243;n beta (TGF-&#946;) en las diversas formas cl&#237;nicas de la enfermedad. Para realizar el estudio, se seleccionaron 50 biopsias de pacientes distribuidos de acuerdo al diagn&#243;stico definido a partir del an&#225;lisis histopatol&#243;gico, seg&#250;n la clasificaci&#243;n de Madrid. Entre las cuatro formas cl&#237;nicas estudiadas, el an&#225;lisis atribuido a los polos de resistencia tuberculoide y de susceptibilidad lepromatosa a partir de la citocina TNF-&#945; indic&#243; un aumento en los niveles de expresi&#243;n de la prote&#237;na de forma tuberculoide de la enfermedad. Referente a la inmunoexpresi&#243;n del TGF-&#946;, la distribuci&#243;n anal&#237;tica entre las cuatro formas cl&#237;nicas present&#243; significado estad&#237;stico entre los grupos estudiados. Sobre las formas polares de la enfermedad, la diferencia entre los grupos demostr&#243; que la participaci&#243;n del TGF-&#946; fue superior en la forma lepromatosa de la enfermedad. En el estudio param&#233;trico abarcando el an&#225;lisis de las variables estudiadas, todas las formas cl&#237;nicas presentaron correlaci&#243;n negativa comprendiendo el crecimiento linear de ambas citocinas. A partir de esos hallazgos, el presente estudio concluye que, durante la evoluci&#243;n espectral de la enfermedad, la actuaci&#243;n de ambas citocinas es fundamental para el control de la respuesta inmunitaria delante del bacilo, reforzando la necesidad de elaborar estudios que complementen la participaci&#243;n de esas mol&#233;culas frente a la fisiopatogenia de la enfermedad.</font></p>     <p><font face="Verdana" size="2"><b>Palabras clave: </b>Lepra; Inmunohistoqu&#237;mica; Factor de Necrosis Tumoral alfa; Factor de Crecimiento Transformador beta.</font></p> <hr size="1" noshade>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>INTRODU&#199;&#195;O</b></font></p>     <p><font face="Verdana" size="2">A hansen&#237;ase &#233; uma doen&#231;a cr&#244;nica granulomatosa causada pelo <i>Mycobacterium leprae, </i>bacilo intracelular</font> <font face="Verdana" size="2">que afeta preferencialmente os nervos perif&#233;ricos e a pele, sendo as vias a&#233;reas superiores a principal porta de entrada e via de elimina&#231;&#227;o do bacilo<sup>1,2,3</sup>.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Clinicamente, a doen&#231;a &#233; caracterizada por apresentar um amplo espectro de formas cl&#237;nicas associadas a altera&#231;&#245;es imunol&#243;gicas do hospedeiro. De acordo com o crit&#233;rio histopatol&#243;gico, estudos sugerem que as formas podem oscilar no espectro da doen&#231;a. Segundo a classifica&#231;&#227;o de Ridley e Jopling, a hansen&#237;ase apresenta cinco formas cl&#237;nicas: hansen&#237;ase tuberculoide (TT), dimorfo tuberculoide (DT), dimorfo dimorfo, (DD), dimorfo lepromatosa (DL) e lepromatosa (LL)<sup>4,5</sup>.</font></p>     <p><font face="Verdana" size="2">Por se tratar de uma doen&#231;a espectral, a resposta imunol&#243;gica do hospedeiro transita entre os extremos da doen&#231;a. Na forma tuberculoide, o indiv&#237;duo apresenta uma intensa resposta celular mediada por linf&#243;citos Th 1 respons&#225;veis pela produ&#231;&#227;o de citocinas pr&#243;-inflamat&#243;rias como o fator de necrose tumoral alfa (TNF-&#945;), que estimula o recrutamento de neutr&#243;filos e mon&#243;citos para o local da infec&#231;&#227;o, ativando-os no intuito de combater o crescimento e multiplica&#231;&#227;o bacteriana no s&#237;tio da infec&#231;&#227;o<sup>6,7</sup>.</font></p>     <p><font face="Verdana" size="2">No polo lepromatoso, a resposta imunol&#243;gica &#233; mediada pelos linf&#243;citos Th2, com a participa&#231;&#227;o de citocinas imunosupressoras como o fator de crescimento transformador beta (TGF-&#946;), respons&#225;vel pelo controle, diferencia&#231;&#227;o, prolifera&#231;&#227;o celular, desenvolvimento e reparo tecidual. Estudos demonstram que a sua atua&#231;&#227;o favoreceria o desenvolvimento da infec&#231;&#227;o<sup>6,8,9</sup>.</font></p>     <p><font face="Verdana" size="2">Sobre as les&#245;es espec&#237;ficas da hansen&#237;ase, estudos indicam que a participa&#231;&#227;o da mol&#233;cula de TNF-&#945; e de seus receptores seria determinante para o aumento da resposta inflamat&#243;ria no local da les&#227;o, sendo que os efeitos de toxicidade direta do TNF-&#945; incluiriam a libera&#231;&#227;o de est&#237;mulos para a produ&#231;&#227;o de outros mediadores que iriam potencializar o dano tecidual, como a IL-1, IL-6 beta, NO e as MMPs. Foi demonstrado que um aumento nas concentra&#231;&#245;es de TNF-&#945; em s&#237;tios lesionados seria capaz de aumentar a infiltra&#231;&#227;o macrof&#225;gica e a dor<sup>10,11,12</sup>.</font></p>     <p><font face="Verdana" size="2">No que tange &#224; participa&#231;&#227;o do TGF-&#946;, a atua&#231;&#227;o de outras citocinas pode vir a modular a resposta celular, causando um efeito diferente, dependendo do estado de ativa&#231;&#227;o da c&#233;lula envolvida. Al&#233;m disso, TGF-&#946; &#233; capaz de promover no tecido inflamado o processo de cicatriza&#231;&#227;o<sup>13</sup> por meio da estimula&#231;&#227;o, regula&#231;&#227;o de matriz extracelular pelos fibroblastos, indu&#231;&#227;o e prolifera&#231;&#227;o de c&#233;lulas endoteliais necess&#225;rias para o processo de angiog&#234;nese<sup>13,14,15</sup>.</font></p>     <p><font face="Verdana" size="2">Diversos estudos demonstram que o desenvolvimento da resposta imunol&#243;gica &#233; um ponto crucial para a media&#231;&#227;o de mecanismos efetores que interferem na resposta fisiopatol&#243;gica frente a determinados pat&#243;genos intracelulares<sup>16</sup>.</font></p>     <p><font face="Verdana" size="2">Dessa forma, diante da din&#226;mica espectral da doen&#231;a, o presente estudo teve como objetivo: avaliar a imunoexpress&#227;o do TNF-&#945; e TGF-&#946; em les&#245;es de pacientes em diversas formas cl&#237;nicas da hansen&#237;ase por meio da t&#233;cnica de imunoistoqu&#237;mica e o seu papel no desenvolvimento da resposta imunol&#243;gica na presen&#231;a do <i>M. leprae.</i></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>MATERIAIS E M&#201;TODOS</b></font></p>     <p><font face="Verdana" size="2"><b>CARACTERIZA&#199;&#195;O DA AMOSTRA</b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Para a realiza&#231;&#227;o do estudo, foram selecionados 50 pacientes com hansen&#237;ase, n&#227;o tratados, atendidos no Ambulat&#243;rio de Dermatologia do N&#250;cleo de Medicina Tropical da Universidade Federal do Par&#225; (UFPA), com idade entre 19 e 55 anos, sendo 19 do sexo masculino e 31 do sexo feminino.</font> <font face="Verdana" size="2">Sobre as formas cl&#237;nicas da doen&#231;a: os pacientes tiveram o diagn&#243;stico confirmado de hansen&#237;ase segundo os crit&#233;rios preconizados pela classifica&#231;&#227;o de Madri. Dentre as formas cl&#237;nicas, dez casos eram de hansen&#237;ase indeterminada (I); 16, de tuberculoide (T); 17, de dimorfo (D); e sete, de lepromatoso (L).</font></p>     <p><font face="Verdana" size="2">Referente &#224;s amostras de pele dos pacientes: as bi&#243;psias cut&#226;neas foram colhidas ap&#243;s antissepsia do local selecionado com PVPI t&#243;pico e anestesia local com lidoca&#237;na a 2% sem vasoconstritor, aplicada por seringa descart&#225;vel de 5 mL e com agulhas 26 G 1/2&quot; 0,45x13 mm. As amostras foram coletadas a partir da sec&#231;&#227;o realizada com <i>punch </i>descart&#225;vel de 4 mm de di&#226;metro.</font></p>     <p><font face="Verdana" size="2">Para a an&#225;lise histopatol&#243;gica das bi&#243;psias emblocadas em material parafinado, foram realizados pelo micr&#243;tomo cortes histol&#243;gicos com 5 &#181;.m de espessura. Para a visualiza&#231;&#227;o no microsc&#243;pio das altera&#231;&#245;es celulares e teciduais dos pacientes, as l&#226;minas foram submetidas &#224; colora&#231;&#227;o pela hematoxilina-eosina (HE) e &#224; imunomarca&#231;&#227;o pela t&#233;cnica de imunoistoqu&#237;mica.</font></p>     <p><font face="Verdana" size="2"><b>T&#201;CNICA DE IMUNOISTOQU&#205;MICA</b></font></p>     <p><font face="Verdana" size="2">Para a realiza&#231;&#227;o, desenvolvimento e descri&#231;&#227;o dos procedimentos adotados na t&#233;cnica, o presente trabalho teve embasamento no protocolo adaptado por Quaresma e colaboradores<sup>16</sup> e o descrito por Hsu e colaboradores<sup>17</sup>.</font></p>     <p><font face="Verdana" size="2">A respeito da avalia&#231;&#227;o da imunomarca&#231;&#227;o do tecido, foi utilizado o m&#233;todo imunoistoqu&#237;mico baseado na forma&#231;&#227;o do complexo ant&#237;geno anticorpo a partir da rea&#231;&#227;o envolvendo a liga&#231;&#227;o entre a estreptavidina-biotina-peroxidase.</font></p>     <p><font face="Verdana" size="2">Inicialmente, os cortes histol&#243;gicos foram desparafinizados em xilol e desidratados em &#225;lcool et&#237;lico. Envolvendo a atividade enzim&#225;tica, o bloqueio da peroxidase end&#243;gena foi feito em c&#226;mara escura, com o per&#243;xido de hidrog&#234;nio a 3%, por 45 min. Para a exposi&#231;&#227;o e a recupera&#231;&#227;o antig&#234;nica do tecido, foi utilizado o tamp&#227;o citrato pH 6,0 a 90<sup>o</sup> C em c&#226;mara de Pascal (DakoCytomation) por 20 min.</font></p>     <p><font face="Verdana" size="2">Referente ao bloqueio das prote&#237;nas inespec&#237;ficas, a fim de se evitar a forma&#231;&#227;o de liga&#231;&#227;o cruzada, as l&#226;minas preparadas foram imersas em solu&#231;&#227;o contendo leite desnatado concentrado a 10% por 30 min. Ap&#243;s esta etapa, os cortes histol&#243;gicos foram preenchidos com os anticorpos prim&#225;rios: Anti-TNF-&#945; (abcam ab6671; dilui&#231;&#227;o: 1:100) e anti-TGF-&#946; (abcam ab66043; dilui&#231;&#227;o: 1:100), dilu&#237;dos em solu&#231;&#227;o a 1% composta por PBS e soro albumina bovina (BSA). Finalizada a aplica&#231;&#227;o, as l&#226;minas foram mantidas em c&#226;mara &#250;mida a 4<sup>o</sup> C por 14 h.</font></p>     <p><font face="Verdana" size="2">Terminada esta etapa, os cortes preenchidos com o anticorpo prim&#225;rio foram imersos em uma solu&#231;&#227;o contendo PBS e, posteriormente, incubados com o anticorpo secund&#225;rio biotinilado LSAB+System HRP (DakoCytomation), por 30 min, na estufa t&#233;rmica a 37<sup>o</sup> C. Ap&#243;s a fixa&#231;&#227;o, os cortes foram novamente imersos em solu&#231;&#227;o de PBS e em seguida incubados com a Streptavidina-Peroxidase LSAB+System HRP (DakoCytomation) por 30 min a 37<sup>o</sup> C. Ap&#243;s este intervalo, os cortes foram revelados com a aplica&#231;&#227;o da</font> <font face="Verdana" size="2">solu&#231;&#227;o crom&#243;gena composta por diaminobenzidina a 0,03% e per&#243;xido de hidrog&#234;nio a 3%.</font></p>     <p><font face="Verdana" size="2">Finalizada esta etapa, os cortes histol&#243;gicos foram submetidos &#224; colora&#231;&#227;o pela hematoxilina de Mayer's, por 3 min, em seguida hidratados em &#225;lcool et&#237;lico e diafanizados em xileno.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><b>AN&#193;LISE        QUANTITATIVA        DAS        C&#201;LULAS</b></font> <b><font face="Verdana" size="2">IMUNOMARCADAS</font></b></p>     <p><font face="Verdana" size="2">Para a contagem dos campos com o tecido imunomarcado, as l&#226;minas foram observadas no microsc&#243;pio &#243;ptico Axio Imager Z1- Zeiss, utilizando oculares A-Plan com leitura realizada em objetiva de 400x.</font></p>     <p><font face="Verdana" size="2">A an&#225;lise quantitativa foi processada de acordo com a intensidade da imunomarca&#231;&#227;o no tecido. Para a confirma&#231;&#227;o de positividade, foram consideradas as c&#233;lulas presente na derme que obtiveram colora&#231;&#227;o acastanhada inequ&#237;voca em um fundo caracter&#237;stico devido &#224; colora&#231;&#227;o pela hematoxilina. A an&#225;lise quantitativa dos eventos foi realizada utilizando o gart&#237;culo graduado com 10x10 subdivis&#245;es (compreendendo uma &#225;rea total de 0,0625 mm<sup>2</sup> da l&#226;mina). Para a an&#225;lise, cinco campos foram selecionados aleatoriamente ao longo de cada &#225;rea da les&#227;o<sup>17,18</sup>.</font></p>     <p><font face="Verdana" size="2"><b>AN&#193;LISE DOS DADOS</b></font></p>     <p><font face="Verdana" size="2">Na an&#225;lise estat&#237;stica dos dados obtidos, o programa Excel 2007 foi utilizado para organizar as planilhas eletr&#244;nicas no intuito de otimizar a elabora&#231;&#227;o de tabelas e gr&#225;ficos. Visando o desenvolvimento e aplica&#231;&#227;o</font> <font face="Verdana" size="2">dos testes estat&#237;sticos, foram utilizados os programas BioEstat 5.0 e GraphPad Prism 5.0. Envolvendo a an&#225;lise univariada, foram obtidas frequ&#234;ncias, medidas de tend&#234;ncia central e de dispers&#227;o, sendo que, para investiga&#231;&#227;o mais detalhada da rela&#231;&#227;o entre as citocinas estudadas e as formas cl&#237;nicas da doen&#231;a apresentadas pelos pacientes, foram aplicados testes de Mann-Whitney, Kruskal-Wallis e a correla&#231;&#227;o de Pearson. Todos os testes foram realizados considerando um n&#237;vel de signific&#226;ncia de 5% (p &lt; 0,05).</font></p>     <p><font face="Verdana" size="2"><b>ASPECTOS &#201;TICOS</b></font></p>     <p><font face="Verdana" size="2">A pesquisa foi aprovada pelo Comit&#234; de &#201;tica em Pesquisa do N&#250;cleo de Medicina Tropical da UFPA (parecer: 047/2008 CEP/NMT).</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>RESULTADOS</b></font></p>     <p><font face="Verdana" size="2">Em rela&#231;&#227;o ao padr&#227;o de resposta imunol&#243;gica, de acordo com o perfil e as formas cl&#237;nicas apresentadas, verificou-se que, dentre os grupos analisados, n&#227;o houve signific&#226;ncia estat&#237;stica, quando comparados de forma geral, envolvendo a imunomarca&#231;&#227;o do anticorpo anti-TNF-&#945;. Segundo os dados, a m&#233;dia das c&#233;lulas contadas nos cinco campos para a forma indeterminada foi de 27,40 e o desvio padr&#227;o de &plusmn; 27,29. Envolvendo a forma tuberculoide, a m&#233;dia obtida foi de 43 c&#233;lulas marcadas e o desvio de &plusmn; 34,79. Na forma dimorfo, a imunomarca&#231;&#227;o para o TNF-&#945; esteve na m&#233;dia de 23,88 das c&#233;lulas marcadas com desvio de &plusmn; 26,08. J&#225; na forma lepromatosa, houve uma m&#233;dia de 7,33, juntamente com desvio apresentado em &plusmn; 7,394 e p = 0,0803 conforme a <a href="#f1">figura 1A</a>.</font></p>     ]]></body>
<body><![CDATA[<p><a name="f1"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/rpas/v4n2/2a06f1.gif" border="0"></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2">Quanto aos polos de resist&#234;ncia, no caso o tuberculoide e o de suscetibilidade o lepromatoso, quando analisados junto ao marcador anti-TNF-&#945;, nas duas formas cl&#237;nicas observou-se signific&#226;ncia estat&#237;stica entre os grupos analisados. De acordo com os dados, a m&#233;dia das c&#233;lulas marcadas na forma tuberculoide foi de 41,85 e desvio padr&#227;o de &plusmn; 35,93. J&#225; no polo lepromatoso, a m&#233;dia foi de 7,33 e o desvio de &plusmn; 7,394 com p = 0,0201 mostrando signific&#226;ncia estat&#237;stica, conforme as <a href="#f1">figuras 1C</a>, <a href="#f2">2B</a>.</font></p>     <p><a name="f2"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/rpas/v4n2/2a06f2.gif" border="0"></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2">Quanto &#224; imunomarca&#231;&#227;o do pept&#237;dio TGF-&#946; a partir do anticorpo anti-TGF-&#946;, as formas cl&#237;nicas, quando analisadas de forma geral, apresentaram diferen&#231;a estat&#237;stica entre si. Na forma indeterminada, o valor</font> <font face="Verdana" size="2">mediano foi de 2 e o desvio padr&#227;o de &plusmn; 2,21 de c&#233;lulas marcadas. No polo tuberculoide, a m&#233;dia foi de 5,53 e o desvio padr&#227;o de &plusmn; 10,67. Na forma dimorfo, a m&#233;dia encontrada foi de 4,93 e o desvio de &plusmn; 6,30. Na hansen&#237;ase lepromatosa, p&#244;de-se observar uma maior concentra&#231;&#227;o do pept&#237;dio, sendo que a m&#233;dia das c&#233;lulas imunomarcadas foi de 9,00 e o desvio de &plusmn; 3,08 com p = 0,0285, como demonstra a <a href="#f1">figura 1B</a>.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">As formas polares apresentaram signific&#226;ncia estat&#237;stica quando comparadas, sendo que na forma tuberculoide o valor mediano foi de 5,53 e o desvio padr&#227;o de &plusmn; 10,67. Na forma lepromatosa, a m&#233;dia das c&#233;lulas marcadas foi de 9 e o desvio padr&#227;o de &plusmn; 3,08, p = 0,0196, como mostrado nas <a href="#f1">figuras 1D</a>, <a href="#f2">2C</a>.</font></p>     <p><font face="Verdana" size="2">Sobre a an&#225;lise param&#233;trica envolvendo a correla&#231;&#227;o linear, n&#227;o houve diferen&#231;a estat&#237;stica entre os grupos estudados. De acordo com os dados, p&#244;de-se observar na forma tuberculoide da doen&#231;a uma correla&#231;&#227;o negativa fraca entre o TNF-&#945; e o TGF-&#946; (r = -0,1037) (p = 0,7360), conforme a <a href="#f3">figura 3A</a>. No polo lepromatoso, o valor do coeficiente de Pearson</font> <font face="Verdana" size="2">demonstrou uma correla&#231;&#227;o negativa moderada entre as duas citocinas estudadas (r = -0,3745), contudo sem signific&#226;ncia estat&#237;stica (p = 0,5346), como mostra a <a href="#f3">figura 3B</a>. Na forma dimorfa e indeterminada, em ambas  a   correla&#231;&#227;o  negativa   encontrada  foi  fraca</font> <font face="Verdana" size="2">(r = -0,1078 e r = -0,1234), (p = 0,6910 e p = 0,7342),</font> <font face="Verdana" size="2">respectivamente, de acordo com a <a href="#f3">figura 3C</a> e <a href="#f3">3D</a>.</font></p>     <p><a name="f3"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/rpas/v4n2/2a06f3.gif" border="0"></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>DISCUSS&#195;O</b></font></p>     <p><font face="Verdana" size="2">A intera&#231;&#227;o existente entre o bacilo e o hospedeiro define um ponto crucial no curso evolutivo da doen&#231;a. De acordo com o grau de aceita&#231;&#227;o ou restri&#231;&#227;o ao crescimento do <i>M. leprae, </i>a presen&#231;a do bacilo retrata a passionalidade e adequa&#231;&#227;o da bact&#233;ria em se estabelecer a partir dos mecanismos de evas&#227;o imunol&#243;gica que o pat&#243;geno consegue desenvolver nos polos de transi&#231;&#227;o da doen&#231;a<sup>19,20</sup>.</font></p>     <p><font face="Verdana" size="2">Os recentes avan&#231;os que foram obtidos em rela&#231;&#227;o ao mecanismo de ades&#227;o do <i>M. leprae </i>demonstram que os componentes lip&#237;dicos micobacterianos interagem com mol&#233;culas espec&#237;ficas da l&#226;mina basal e das c&#233;lulas de</font> <font face="Verdana" size="2">Schwann<sup>21,22,23</sup>.</font></p>     <p><font face="Verdana" size="2">Durante o curso progressivo da infec&#231;&#227;o, a micobacteria consegue estimular receptores de sinaliza&#231;&#227;o espec&#237;ficos que interferem na indu&#231;&#227;o seletiva de genes do hospedeiro que facilitam a invas&#227;o, coloniza&#231;&#227;o e crescimento bacteriano<sup>24</sup>.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Dependendo da forma cl&#237;nica apresentada, o bacilo consegue modular o padr&#227;o de resposta imunol&#243;gica de acordo com o s&#237;tio de express&#227;o de determinados receptores<sup>22,25</sup>.</font></p>     <p><font face="Verdana" size="2">No intuito de se compreender melhor de que maneira a resposta imunol&#243;gica evolui perante a din&#226;mica espectral da doen&#231;a a partir das altera&#231;&#245;es fisiopatol&#243;gicas provocadas pelo <i>M. leprae, </i>este trabalho avaliou a imunoexpress&#227;o do TNF-&#945;, TGF-&#946; e o comprometimento</font> <font face="Verdana" size="2">das les&#245;es de pele de pacientes nas diversas formas cl&#237;nicas da doen&#231;a pela t&#233;cnica de imunoistoqu&#237;mica<sup>16</sup>.</font></p>     <p><font face="Verdana" size="2">No presente estudo, os resultados demonstram que a imunoexpress&#227;o do TNF-&#945; foi maior na forma tuberculoide do que na lepromatosa da doen&#231;a (41,85 &plusmn; 35,93 <em>versus</em> 7,333 &plusmn; 7,394 c&#233;lulas/campo; p = 0,0201). Estes achados podem ser explicados a partir do perfil de resposta imunol&#243;gica que &#233; desenvolvida no polo tuberculoide da doen&#231;a. Estudos retratam que a imunoexpress&#227;o do TNF-&#945; estimula a resposta relacionada ao perfil Th1 pr&#243;-inflamat&#243;rio, estimulando o recrutamento de macr&#243;fagos, aumentando a produ&#231;&#227;o de NO no local da infec&#231;&#227;o<sup>25,26</sup>.</font></p>     <p><font face="Verdana" size="2">Pesquisas t&#234;m demonstrado que esta citocina &#233; fundamental para o combate da prolifera&#231;&#227;o bacilar. De acordo com Santos e colaboradores<sup>27</sup>, em estudo envolvendo les&#245;es de pacientes multi e paucibacilares, foi observado que a imunoexpress&#227;o do TNF-&#945; sob a altera&#231;&#227;o da regi&#227;o promotora (-308G/A) da prote&#237;na era mais frequente em pacientes multibacilares. Nos estudos desenvolvidos por Sarno e colaboradores<sup>28</sup>, verificou-se que, em pacientes multibacilares, a altera&#231;&#227;o na produ&#231;&#227;o do gene TNF nos macr&#243;fagos proporcionaria um ambiente privilegiado para a manuten&#231;&#227;o do bacilo, favorecendo a persist&#234;ncia da infec&#231;&#227;o.</font></p>     <p><font face="Verdana" size="2">Nas altera&#231;&#245;es teciduais que s&#227;o provocadas perante o dano neural, vale ressaltar que a participa&#231;&#227;o da mol&#233;cula de TNF-&#945;, quando produzida de forma inapropriada, acarreta complica&#231;&#245;es severas, envolvendo o desenvolvimento das c&#233;lulas de Schwann. Segundo os avan&#231;os obtidos a partir da compreens&#227;o molecular a respeito da express&#227;o celular, estudos demonstram que as les&#245;es provocadas pelo bacilo apresentam uma eleva&#231;&#227;o na produ&#231;&#227;o de linf&#243;citos CD4+, de HLA-DR, do receptor IL-2, em c&#233;lulas do infiltrado, assim como nos ceratin&#243;citos<sup>6,29,30,31,32</sup>.</font></p>     <p><font face="Verdana" size="2">Quanto &#224; an&#225;lise sobre as circunst&#226;ncias eventuais a partir das altera&#231;&#245;es histopatol&#243;gicas, foi demonstrado que o TNF-&#945; atua de forma sin&#233;rgica e aut&#243;crina com outras citocinas, estimulando a forma&#231;&#227;o do granuloma no local da les&#227;o<sup>33,34</sup>.</font></p>     <p><font face="Verdana" size="2">Estudos desenvolvidos sobre o remodelamento tecidual demonstram que a participa&#231;&#227;o do TNF-&#945; contribui de forma direta para o aumento da express&#227;o das MMPs nesta forma cl&#237;nica da doen&#231;a, aumentando o efeito citol&#237;tico das c&#233;lulas, bem como a degrada&#231;&#227;o da matriz tecidual da derme papilar<sup>11,35,36</sup>.</font></p>     <p><font face="Verdana" size="2">Sobre os eventos referentes &#224; morte celular programada, j&#225; se demonstrou que, em culturas de mon&#243;citos dose-dependentes, a participa&#231;&#227;o do TNF-&#945; estimularia o aumento nas concentra&#231;&#245;es do BAX na forma lepromatosa da doen&#231;a, o que refor&#231;a a atua&#231;&#227;o desta citocina como uma importante protagonista da resposta fisiopatol&#243;gica envolvendo a hansen&#237;ase<sup>16,37</sup>.</font></p>     <p><font face="Verdana" size="2">Referente &#224; participa&#231;&#227;o do TGF-&#946;, nos estudos desenvolvidos sobre sua fun&#231;&#227;o, procurou-se entender a diferen&#231;a existente entre as formas tuberculoide e lepromatosa ao correlacionarem-se &#224; express&#227;o de outros fatores de a&#231;&#227;o antimicrobicida. Segundo os nossos   achados, an&#225;lise demonstrou que na forma lepromatosa</font> <font face="Verdana" size="2">da doen&#231;a, a concentra&#231;&#227;o de c&#233;lulas por campo foi maior do que na tuberculoide (9,00 &plusmn; 3,08 <i>versus</i></font> <font face="Verdana" size="2">5,53 &plusmn; 10,67 c&#233;lulas/campo; p = 0,0196).</font></p>     <p><font face="Verdana" size="2">Os estudos desenvolvidos por Goulart e colaboradores<sup>30</sup> demonstram que o TGF-&#946; impediria a express&#227;o do &#243;xido n&#237;trico e sua a&#231;&#227;o antimicrobiana ao contrapor-se a citocinas mediadoras da resposta Th1. Neste sentido, o TGF-&#946; favorece o padr&#227;o de resposta Th2 nas formas lepromatosa e dimorfo lepromatosa, enquanto que nas formas tuberculoide e dimorfo tuberculoide encontra-se com a express&#227;o diminu&#237;da ou suprimida<sup>38,39,40</sup>. Sobre as dosagens do pept&#237;dio, os estudos demonstram elevadas concentra&#231;&#245;es nas culturas de c&#233;lulas aderentes de mon&#243;citos no sangue perif&#233;rico de pacientes com hansen&#237;ase dimorfo lepromatosa e lepromatosa que entraram em rea&#231;&#227;o hans&#234;nica do tipo 2 ou do eritema nodoso, adquirindo n&#227;o s&#243; papel supressor, como tamb&#233;m inflamat&#243;rio<sup>30,40,41,42</sup>.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Os resultados alcan&#231;ados com este estudo encontraram concord&#226;ncia com trabalhos presentes na literatura, bem como nos primeiros postulados sobre a imunopatogenia do TGF-&#946;. Nestes estudos, a fun&#231;&#227;o do pept&#237;dio ganha refor&#231;o como um forte indutor do padr&#227;o de resposta Th2 e antagonista &#224; libera&#231;&#227;o de esp&#233;cies reativas intermedi&#225;rias de oxig&#234;nio e nitrog&#234;nio, ao ser correlacionado &#224;s presen&#231;as da enzima &#243;xido n&#237;trico sintetase (iNOS) e das citocinas IFN-&#947; e TNF-&#945;<sup>43,44,45,46</sup>.</font></p>     <p><font face="Verdana" size="2">Estudos demonstram que a participa&#231;&#227;o do TGF-&#946; pode ser um importante indutor para a produ&#231;&#227;o de est&#237;mulos que desencadeiem a altera&#231;&#227;o na produ&#231;&#227;o do col&#225;geno dos tipos 1 e 3 no espa&#231;o mesenquimal do epit&#233;lio, estimulando o aumento da produ&#231;&#227;o de RNA mensageiro das MMPs, bem como na produ&#231;&#227;o do fator de crescimento do nervo nas c&#233;lulas de Schwann. Estudos retratam que esta citocina pode orquestrar eventos que incluem reprograma&#231;&#227;o do fen&#243;tipo das c&#233;lulas, levando &#224; transdiferencia&#231;&#227;o de fen&#244;menos que interfiram na expans&#227;o de c&#233;lulas de tecido conjuntivo, na fibrog&#234;nese, na evolu&#231;&#227;o das les&#245;es dos nervos e na morte celular programada durante o curso progressivo da doen&#231;a<sup>47,48,49</sup>.</font></p>     <p><font face="Verdana" size="2">Referente aos eventos apopt&#243;ticos, atualmente alguns autores tentam explicar a atua&#231;&#227;o do TGF-&#946; no desenvolvimento de mecanismos de morte celular, durante evolu&#231;&#227;o espectral da hansen&#237;ase. Estudos demonstram que o TGF-&#946; pode ser um importante indutor de apoptose na forma lepromatosa da doen&#231;a sendo que, nesta forma cl&#237;nica, o TGF-&#946; aumentaria a ativa&#231;&#227;o de quinases e o clivamento da caspase 3, aumentando a ativa&#231;&#227;o dos dom&#237;nios de morte nos processos cr&#244;nicos e infecciosos da doen&#231;a<sup>50,51,52</sup>.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>CONCLUS&#195;O</b></font></p>     <p><font face="Verdana" size="2">Dessa forma, o presente estudo conclui que a participa&#231;&#227;o de ambas as citocinas via condicionamento, adapta&#231;&#227;o, adequa&#231;&#227;o e sinaliza&#231;&#227;o pode interferir diretamente no perfil de resposta imunol&#243;gica desenvolvida na imunopatogenia da hansen&#237;ase, refor&#231;ando ainda mais o processo de complexidade sobre a an&#225;lise dos marcadores imunol&#243;gicos durante o curso evolutivo da doen&#231;a.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="3"><b>REFER&#202;NCIAS</b></font></p>     <!-- ref --><p><font face="Verdana" size="2">1 Minist&#233;rio da Sa&#250;de (BR). Secretaria de Pol&#237;ticas de Sa&#250;de. Departamento de Aten&#231;&#227;o B&#225;sica. Guia para o controle da hansen&#237;ase. 3. ed. Bras&#237;lia: Minist&#233;rio da Sa&#250;de; 2002. 89 p. &#91;<a href="http://bvsms.saude.gov.br/bvs/publicacoes/guia_de_hanseniase.pdf" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">2 Organiza&#231;&#227;o Mundial da Sa&#250;de. A estrat&#233;gia global para aliviar a carga da hansen&#237;ase e manter as atividades de controle da hansen&#237;ase; 2005. 27 p. &#91;<a href="http://www.saude.sp.gov.br/resources/ses/perfil/gestor/documentos-tecnicos/informes-tecnicos/estrategia_global_para_controle_de_hanseniase.pdf" target="_blank">Link&#93;</a></font><!-- ref --><p><font face="Verdana" size="2">3&nbsp;Ara&#250;jo MG. Hansen&#237;ase no Brasil. Rev Soc Bras Med Trop. 2003 mai-jun;36(3):373-82. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Rev+Soc+Bras+Med+Trop.+2003%3B36%283%29%3A373-382." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">4&nbsp;Ishii N. Recent advances in the treatment of leprosy. Dermatol Online J. 2003;9(2):5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Ishii+N.+Recent+advances+in+the+treatment+of+leprosy" target="_blank">&#91;Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">5&nbsp;Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255-73. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Int+J+Lepr+Other+Mycobact+Dis.+1966%3B34%3A255%E2%80%9373" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">6&nbsp;Mendonca VA, Costa RD, Melo GEBA, Antunes CM, Teixeira AT. Imunologia da hansen&#237;ase. An Bras Dermatol. 2008 jul-ago;83(4):343-50. &#91;<a href="http://www.anaisdedermatologia.org.br/public/artigoprev.aspx?id=100890" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">7&nbsp;Andersson AK, Chaduvula M, Atkinson SE, Khanolkar-Young S, Jain S, Suneetha L, et al. Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun.</font> <font face="Verdana" size="2">2005 Jun;73(6):3725-33. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Anna+KA%2C+MeherVani+C%2C+Sara+EA%2C+Saroj+KY%2C+Suman+J%2C+Lavanya+S%2C+et+al.+Effects+of+prednisolone+treatment+on+cytokine+expression+in+patients+with+leprosy+type+1+reactions" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">8&nbsp;Kingsley DM. The TGF-&#946; superfamily: new members, new receptors and new genetic tests of function in different organisms. Genes Dev. 1994 Jan;8(2):133-46. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Genes+Dev.+1994%3B8%3A133-146" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">9&nbsp;Letterio JJ, Roberts AB. Regulation of immune responses by TGF-&#946;. Annu Rev Immunol. 1998;16:137-61.<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Annual+Review+Immunology.+1998%3B16%3A137-61." target="_blank"> &#91;Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">10&nbsp;Harris JE, Fernandez-Vilaseca M, Elkington PTG, Horncastle DE, Graeber MB, Friedland JS. IFN-&#947; synergizes with IL-1 &#946; to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis. FASEB J. 2007 Feb;21(2):356-65. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=IFNgamma+synergizes+with+IL-+1beta+to+up-regulate+MMP-9+secretion+in+a+cellular+model+of+central+nervous+system+tuberculosis" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">11&nbsp;Teles RMB, Teles RB, Amadeu TP, Moura DF,</font> <font face="Verdana" size="2">Mendon&#231;a-Lima L,&nbsp;Ferreira H, et al. High matrix</font> <font face="Verdana" size="2">metalloproteinase&nbsp;production     correlates     with</font> <font face="Verdana" size="2">immune   activation&nbsp;and   leukocyte   migration   in</font> <font face="Verdana" size="2">leprosy   reactional&nbsp;lesions.   Infect   Imunn.   2010</font> <font face="Verdana" size="2">Mar;78(3):1012-21. Doi:10.1128/IAI.00896-09 &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Infect+Imunn.+2010+Mar%3B78%283%29%3A1012-21http://iai.asm.org/content/78/3/1012.full.pdf" target="_blank">Link&#93;</a></font><!-- ref --><p><font face="Verdana" size="2">12&nbsp;Fayyazi A, Schweyer S, Eichmeyer B, Herms J, Hemmerlein B, Radzun HJ. Expression of IFN-&#947;, coexpression of TNF-&#945; and matrix metalloproteinases and apoptosis of T lymphocytes and  macrophages  in  granuloma  annulare. Arch</font> <font face="Verdana" size="2">Dermatol Res. 2000 Aug;292(8):384-90. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Expression+of+IFN-gamma%2C+coexpression+of+TNF-alpha+and+matrix+metalloproteinases+and+apoptosis+of+T+lymphocytes+and+macrophages+in+granuloma+annulare" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">13&nbsp;Parks WC, Wilson CL, L&#243;pez-Boado YS. Matrix metalloproteinases as modulators of inflammation and   innate   immunity.   Nat  Rev   Immunol.   2004</font> <font face="Verdana" size="2">Aug;4(8):617-29. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Matrix+metalloproteinases+as+modulators+of+inflammation+and+innate+immunity+N.+Immunol.+2004%3B4%3A617-629" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">14&nbsp;Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion:  role</font> <font face="Verdana" size="2">for cell migration. Pathol Int. 2002 Apr;52(4):255-64. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Pathol+Int.+2002%3B52%284%29%3A255-64." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">15&nbsp;Unemori EN, Hibbs MS, Amento EP. Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in   normal   human   fibroblasts   by   inflammatory</font> <font face="Verdana" size="2">cytokines. J Clin Invest. 1991 Nov;88(5):1656-62. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Constitutive+11.+expression+of+a+92-kD+gelatinase+%28type+V+collagenase%29+by+rheumatoid+synovial+fibroblasts+and+its+induction+in+normal+human+fibroblasts+by+inflammatory+cytokines" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">16&nbsp;Quaresma JA, Lima LW, Fuzii HT, Libonati RM, Pagliari C, Duarte MI. Immunohistochemical evaluation of macrophage activity and its relationship with apoptotic cell death in the polar forms of leprosy. Microb Pathog. 2010 Oct;49(4):</font><font face="Verdana" size="2">135-40. Doi:10.1016/j.micpath.2010.05.003. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Microbial+Pathogenesis.+2010%3B49%3A+135-140" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">17&nbsp;Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem</font><font face="Verdana" size="2"> Cytochem. 1981 Apr;29(4):577-80. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Histochem+Cytochem.+1981%3B29%3A577-80." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">18&nbsp;Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ.</font> <font face="Verdana" size="2">Catalyzed reporter deposition, a novel method of signal amplification: application to immunoassays.</font> <font face="Verdana" size="2">J Immunol Methods. 1989 Dec;125(1-2):279-85. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Catalyzed+reporter+deposition%2C+a+novel+method+of+signal+amplification.+Application+to+immunoassays.+J+Immunol+Methods.+1989%3B125%3A279-85." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">19&nbsp;Cabello PH. Fatores gen&#233;ticos nas doen&#231;as infecciosas e parasit&#225;rias. In: Coura JR . Din&#226;mica das doen&#231;as infecciosas e parasit&#225;rias. Rio de Janeiro: Guanabara</font> <font face="Verdana" size="2">Koogan; 2005.</font><!-- ref --><p><font face="Verdana" size="2">20&nbsp;Rambukkana A, Zanazzi G, Tapinos N, Salzer JL. Contact-dependent demyelination by <i>Mycobacterium leprae </i>in the absence of immune cells. Science. 2002 May 3;296(5569):927-31. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Rambukkana+A%2C+Zanazzi+G%2C+Tapinos+N%2C+Salzer+JL.+Contact-dependent+demyelination+by+Mycobacterium+leprae+in+the+absence+of+immune+cells.+Science.+2002%3B296%3A927%E2%80%9393" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">21&nbsp;Adams LB, Fukutomi Y, Krahenbuhl JL. Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence. Infect Immun. 1993 Oct;61(10):4173-81. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Infect+Immun.+1993%3B61%3A4173&ndash;4181" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">22&nbsp;Brennan PJ, Vissa VD. Genomic evidence for the retention of the essential mycobacterial cell wall in the otherwise defective <i>Mycobacterium leprae. </i>Lepr Rev. 2001 Dec;72(4):415-28. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Leprosy+Review.+2001%3B72%3A+415&ndash;28" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">23&nbsp;Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, Sharfstein SE, et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med. 2005 Jun;11(6):653-60. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Nat+Med.+2005%3B11%3A653-60" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">24&nbsp;Alter A, Leseleuc L, Van Thuc N, Thai VH, Huong NT, Ba NN, et al. Genetic and functional analysis of common <i>MRC1 </i>exon 7 polymorphisms in leprosy susceptibility. Hum Genet. 2010 Mar;127(3):337-48. Doi:10.1007/s00439-009-0775-x. <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Hum.+Genet.+127%3A+337&ndash;348" target="_blank">&#91;Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">25&nbsp;Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J</font> <font face="Verdana" size="2">Leukoc Biol. 2007 Dec;82(6):1375-81. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Philippe+VL%2C+Claude+L.+Chemokine+and+cytokine+processing+by+matrix+metalloproteinases+and+its+effect+on+leukocyte+migration+and+inflammation" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">26&nbsp;Takeichi O, Saito I, Okamoto Y, Tsurumachi T, Saito T. Cytokine regulation on the synthesis of nitric oxide <i>in vivo </i>by chronically infected human polymorphonuclear leucocytes. Immunology.  1998</font> <font face="Verdana" size="2">Feb;93(2):275-80.  &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Cytokine+regulation+on+the+synthesis+of+nitric+oxide+in+vivo+by+chronically+infected+human+polymorphonuclear+leucocytes" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">27&nbsp;Santos AR, Suffys PN, Vanderborght PR, Moraes MO, Vieira LMM, Cabello PH, et al. Role of tumor</font> <font face="Verdana" size="2">necrosis factor-&#945; and interleukin-10 promoter gene polymorphisms in leprosy. J Infect Dis. 2002</font> <font face="Verdana" size="2">Dec;186(11):1687-91. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Santos+AR,+Suffys+PN,+Vanderborght+PR,+Moraes+MO,+Vieira+LM,+Cabello+PH.+Role+of+tumor+necrosis+factor-alpha+and+interleukin-10+promoter+gene+polymorphisms+in+leprosy" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">28&nbsp;Sarno EN, Santos AR, Jardim MR, Suffys PN, Almeida</font> <font face="Verdana" size="2">AS, Nery JAC, et al. Pathogenesis of nerve damage in leprosy: genetic polymorphism regulates the production of TNF alpha. Lepr Rev. 2000 Dec;71</font> <font face="Verdana" size="2">Suppl:154-8. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Pathogenesis+of+nerve+damage+in+leprosy%3A+genetic+polymorphism+regulates+the+production+of+TNF%CE%B1.+Lepr+Rev.+2000+Dec%3B71+Suppl%3AS154-8.+%5bLink%5d" target="_blank">Link&#93;</a></font><!-- ref --><p><font face="Verdana" size="2">29&nbsp;Litle D, Khanolkar-Young S, Coulthart A, Suneetha S, Lockwood DN. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12 and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun.</font> <font face="Verdana" size="2">2001 May;69(5):3413-7. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Infect+Immun.+2001%3B69%285%29%3A3413-7." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">30&nbsp;Goulart IM, Penna GO, Cunha G. Imunopatologia da hanseniase: a complexidade da resposta imune do hospedeiro ao <i>Mycobacterium leprae. </i>Rev Soc Bras Med Trop. 2002 jul-ago;35(4):365-75. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Goulart+IMB%2C+Penna+GO%2C+Cunha+G.+http://www.ncbi.nlm.nih.gov/pubmed/?term=Goulart+IMB%2C+Penna+GO%2C+Cunha+G.+Imunopatologia+da+hanseniase%3A+a+complexidade+da+resposta+imune+do+hospedeiro+ao+Mycobacterium+leprae" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">31&nbsp;Kahawita IP, Walker SL, Lockwood DNJ. Leprosy type 1  reactions and erythema nodosum leprosum. An</font> <font face="Verdana" size="2">Bras Dermatol. 2008 Jan-Fev;83(1):75-82. Doi:10.1590/S0365-05962008000100010. <a href="http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962008000100010" target="_blank">&#91;Link&#93; </a></font><!-- ref --><p><font face="Verdana" size="2">32&nbsp;Modlin RL, Melancon-Kaplan J, Young SMM, Pirmez C, Kino H, Convit J, et al. Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1213-7. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Learning+from+lesions%3A+patterns+of+tissue+inflammation+in+leprosy.+Proc+Natl+Acad+Sci+USA.+1988;85%3A1213-7." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">33&nbsp;Pena M, Geluk A, Van Der Ploeg-Van Schip JJ, Franken KL, Sharma R, Truman R. Cytokine responses to <i>Mycobacterium leprae </i>unique proteins differentiate between <i>Mycobacterium leprae </i>infected and naive armadillos. Lepr Rev. 2011   Dec;82(4):</font><font face="Verdana" size="2">422-31. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Lepr+Rev.+2011%3B82(4)%3A422-31." target="_blank">Link</a>&#93; </font><!-- ref --><p><font face="Verdana" size="2">34&nbsp;Freitas DS, Machado N, Andrigueti FV, Reis Neto ET, Pinheiro MM. Lepromatous leprosy associated with the use of anti-TNF a therapy: case report. Rev Bras</font> <font face="Verdana" size="2">Reumatol. 2010 May-Jun;50(3):333-9. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=.+Rev.+Bras.+Reumatol.+2010%3B50(3)%3A333-339." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">35&nbsp;Oliveira AL, Antunes SL, Teles RM, Silva AC, Silva TP, Brand&#227;o Teles R. Schwann cells producing matrix metalloproteinases under <i>Mycobacterium leprae </i>stimulation may play a role in the outcome of leprous neuropathy. J Neuropathol Exp Neurol. 2010 Jan;69(1):27-39. Doi:10.1097/NEN.0b013e3181c6515c.  &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Schwann+cells+producing+matrix+metalloproteinases+under+Mycobacterium+leprae++stimulation+may+play+a+role+in+the+outcome+of+leprous+neuropathy.+J+Neuropathol+Exp+Neurol.+2010%3B69(1)%3A27-" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">36&nbsp;Steenport M, Khan KMF, Du B, Barnhard SE, Dannenberg AJ, Falcone DJ. Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-&#945; and cyclooxygenase-2. J Immunol. 2009 Dec;183(12):8119-27. Doi:10.4049/jimmunol.0901925. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Metalloproteinase+MMP-1+and+MMP-3+Induce+Macrophage+MMP-9%3A+evidence+for+the+role+of+TNF-%CE%B1+and+cyclooxygenase-2.+J+Immunol.183%3A+8119-8127%2C+2009." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">37&nbsp;Hernandez MO, Neves I, Sales JS, Carvalho DS, Sarno EN, Sampaio EP. Induction of apoptosis in monocytes by <i>Mycobacterium leprae in vitro</i>: a possible role for tumor necrosis factor-&#945;. Immunology. 2003 May;109(1):156-64. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Induction+of+apoptosis+in+monocytes+by+Mycobacterium+leprae+in+vitro%3A+a+possible+role+for+tumor+necrosis+factor-alpha.+Immunology+2003%3B109%3A156-64." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">38&nbsp;Green SJ, Scheller LF, Marletta MA, Seguin MC, Klotz FW, Slayter M, et al. Nitric oxide: cytokine-regulation of nitric oxide in  host resistance to intracellular</font> <font face="Verdana" size="2">pathogens. Immunol Lett. 1994 Dec;43(1-2):87-94. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Nancy+CA.+Nitric+oxide%3A+cytokine-regulation+of+nitric+oxide+in+host+resistance+to+intracellular+pathogens.+Immunology+Letters.+1994%3B43%3A87-94." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">39&nbsp;Williams AO, Chanock S, Flanders KC. Transforming growth factor beta isoforms in tuberculoid and leprometous leprosy: immunohistochemical studies.</font> <font face="Verdana" size="2">Cell Vision. 1995;2:363.</font><!-- ref --><p><font face="Verdana" size="2">40&nbsp;Kiszewski CA, Becerril E, Baquera L, Aguilar LD, Hern&#225;ndez-Pando R. Expression of transforming growth fator-&#946; isoforms and their receptors in lepromatous   and   tuberculoid   leprosy.   Scand   J </font><font face="Verdana" size="2">Immunol. 2003 Mar;57(3):279-85. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Scandinavian+Journal+of+Immunology.+2002%3B57%3A279-285." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">41&nbsp;Goulart IMB, Figueiredo F, Coimbra T, Foss NT. Detection of transforming growth factor-&#946;1 in dermal lesions of different clinical forms of leprosy. Am J</font> <font face="Verdana" size="2">Pathol. 1996 Mar;148(3):911-7. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Detection+of+transforming+growth+factor-b1+in+dermal+lesions+of+different+clinical+forms+of+leprosy.+American+Journal+of+Pathology.+1996%3B148%3A911-917." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">42&nbsp;Goulart IMB, Mineo JR, Foss NT. Production of</font> <font face="Verdana" size="2">transforming growth factor-beta 1 (TGF-&#946;1) by blood monocytes from patients with different clinical forms of leprosy. Clinical and Experimental Immunology.</font> <font face="Verdana" size="2">2000 Dec;122(2):330-4. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Experimental+Immunology.+2000%3B122%3A330-334" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">43&nbsp;McCartney-Francis N, Mizel D, Wong H, Wahl L, Wahl S. TGF-&#946; regulates production of growth factors and TGF-&#946; by human peripheral blood monocytes. Growth Factors. 1990;4(1):27-35. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Growth+Factors.+1990;4%3A27–35." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">44&nbsp;Khanolkar-Young S, Snowdon D, Lockwood DN. Immunocytochemical localization of inducible nitric oxide synthase and transforming growth factor-beta (TGF-&#946;) in leprosy lesions. Clin Exp Immunol. 1998 Sep;113(3):438-42. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=.+Immunocytochemical+localization+of+inducible+nitric+oxide+synthase+and+transforming+growth+factor-beta+(TGF-ß1+in+leprosy+lesions.+Clin+Exp+Immunol+1998;113%3A438-442." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">45&nbsp;Venturini J. Boderline leprosy: in situ and cytokine profile in supernatant of mononuclear cell culture. J Venom Anim Toxins Incl Trop Dis. 2009;15(2):366. Doi:10.1590/S1678-91992009000200018. &#91;<a href="http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992009000200018&lng=en&nrm=iso&tlng=en" target="_blank">Link</a>&#93;&nbsp; </font><!-- ref --><p><font face="Verdana" size="2">46&nbsp;Adams LB, Job CK, Krahenbuhl JL. Role of inducible nitric oxide synthase inresistance to <i>Mycobacterium leprae </i>in  mice.   Infect Immun.  2000 Sep;68(9):</font><font face="Verdana" size="2">5462-5. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Infect+Immun+2000%3B68%3A5462-5." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">47&nbsp;Petito RB, Amadeu TP, Pascarelli B, Jardim MR, Vital RT, Antunes SL, et al. Transforming growth factor-&#946;1 may be a key mediator of the fibrogenic properties of neural cells in leprosy. J Neuropathol Exp Neurol.</font> <font face="Verdana" size="2">2013 Apr;72(4):351-66. Doi:10.1097/NEN.0b013e31828bfc60. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Neuropathol+Exp+Neurol.+2013%3B72(4)%3A351-66." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">48&nbsp;Moura DF, Mattos KA, Amadeu TP, Andrade PR, Sales</font> <font face="Verdana" size="2">JS, Schmitz V, et al. CD163 favors <i>Mycobacterium leprae </i>survival and persistence by promoting anti-inflammatory pathways in lepromatous macrophages.</font> <font face="Verdana" size="2">Eur J Immunol. 2012 Nov;42(11):2925-36. Doi:10.1002/eji.201142198. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Eur+J+Immunol.+2012%3B42(11)%3A2925-36." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">49&nbsp;Kim M, Shin DW, Shin H, Noh M, Shin JH. Tensile</font> <font face="Verdana" size="2">stimuli increase nerve growth factor in human dermal fibroblasts  independent of tension-induced  TGF&#946;</font> <font face="Verdana" size="2">production. Exp Dermatol. 2013;22(1):72-4. Doi:10.1111/exd.12064. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Exp+Dermatol.+2013%3B22(1)%3A72-4." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">50&nbsp;Quaresma JAS, Almeida FAC, Aarao TLS, Soares LPMA, Magno IMN, Fuzii HT, et al. Transforming growth factor &#946; and apoptosis in leprosy skin lesions: possible relationship with the control of the tissue immune   response   in   the <i>Mycobacterium   leprae</i></font> <font face="Verdana" size="2">infection. Microbes Infect. 2012 Aug;14(9):696-701. Doi:10.1016/j.micinf.2012.02.010. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Microbes+Infect.+2012%3B14(9)%3A696-701." target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">51&nbsp;Brown TL, Patil S, Cianci CD, Morrow JS, Howe PH. Transforming growth factor &#946; induces caspase 3-independent cleavage of &#945;ll-spectrin (&#945;-fodrin) coincident with apoptosis. J Biol Chem. 1999 Aug</font> <font face="Verdana" size="2">13;274(33):23256-62. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=J+Biol+Chem.+1999+Aug+13%3B274(33)%3A23256-62" target="_blank">Link</a>&#93;</font><!-- ref --><p><font face="Verdana" size="2">52&nbsp;Oliveira RB, Sampaio EP, Aarestrup F, Teles RMB, Silva TP, Oliveira AL, et al. Cytokines and <i>Mycobacterium leprae   </i>induce  apoptosis   in   human  Schwann.  J</font><font face="Verdana" size="2"> Neuropathol Exp Neurol. 2005 Oct;64(10):882-90. &#91;<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=.+J+Neuropathol+Exp+Neurol.+2005%3B64(10)%3A882-90" target="_blank">Link</a>&#93;</font><p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="verdana"><b><b><b><b><a name="endereco"></a><a href="#topo"><img src="img/revistas/ess/v20n1/seta.gif" border="0"></a></b></b></b></b></font><font face="Verdana" size="2"><b>Correspond&#234;ncia / Correspondence / Correspondencia:</b></font>    <br> <font face="Verdana" size="2">Juarez Ant&#244;nio Sim&#245;es Quaresma    <br> Universidade Federal do Par&#225;</font>    <br> <font face="Verdana" size="2">N&#250;cleo de Medicina Tropical,    <br> Laborat&#243;rio de Imunopatologia    <br> Av. General&#237;ssimo Deodoro, 92.    <br> Bairro: Umarizal CEP: 66055-240    <br> Bel&#233;m-Par&#225;-Brasil    ]]></body>
<body><![CDATA[<br> Tel.: +55 (91) 3241-4681</font>    <br> <font face="Verdana" size="2">E-mail: <a href="mailto:&#161;uarez@ufpa.br">&#161;uarez@ufpa.br</a> / <a href="mailto:juarez@pesquisador.cnpq.br">juarez@pesquisador.cnpq.br</a></font></p>     <p><font face="Verdana" size="2">Recebido em / Received / Recibido en: 2/5/2013    <br> Aceito em / Accepted / Aceito en: 12/6/2013</font></p> <script type="text/javascript"> var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); </script> <script type="text/javascript"> try { var pageTracker = _gat._getTracker("UA-7885746-4"); pageTracker._setDomainName("none"); pageTracker._setAllowLinker(true); pageTracker._trackPageview(); } catch(err) {}</script>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR)^dSecretaria de Políticas de Saúde. Departamento de Atenção Básica</collab>
<source><![CDATA[Guia para o controle da hanseníase]]></source>
<year>2002</year>
<edition>3</edition>
<page-range>89</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Organização Mundial da Saúde</collab>
<source><![CDATA[A estratégia global para aliviar a carga da hanseníase e manter as atividades de controle da hanseníase]]></source>
<year>2005</year>
<page-range>27</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Hanseníase no Brasil]]></article-title>
<source><![CDATA[Rev Soc Bras Med Trop]]></source>
<year>2003</year>
<month> m</month>
<day>ai</day>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>373-82</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ishii]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recent advances in the treatment of leprosy]]></article-title>
<source><![CDATA[Dermatol Online J]]></source>
<year>2003</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>5</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridley]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Jopling]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Classification of leprosy according to immunity: a five-group system]]></article-title>
<source><![CDATA[Int J Lepr Other Mycobact Dis]]></source>
<year>1966</year>
<month> J</month>
<day>ul</day>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>255-73</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendonca]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[GEBA]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Teixeira]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Imunologia da hanseníase]]></article-title>
<source><![CDATA[An Bras Dermatol]]></source>
<year>2008</year>
<month> j</month>
<day>ul</day>
<volume>83</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>343-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersson]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Chaduvula]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Atkinson]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Khanolkar-Young]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Suneetha]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>2005</year>
<month> J</month>
<day>un</day>
<volume>73</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>3725-33</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kingsley]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The TGF-&#946; superfamily: new members, new receptors and new genetic tests of function in different organisms]]></article-title>
<source><![CDATA[Genes Dev]]></source>
<year>1994</year>
<month> J</month>
<day>an</day>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-46</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Letterio]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Regulation of immune responses by TGF-&#946;]]></article-title>
<source><![CDATA[Annu Rev Immunol]]></source>
<year>1998</year>
<volume>16</volume>
<page-range>137-61</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez-Vilaseca]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elkington]]></surname>
<given-names><![CDATA[PTG]]></given-names>
</name>
<name>
<surname><![CDATA[Horncastle]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Graeber]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Friedland]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IFN-&#947; synergizes with IL-1 &#946; to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis]]></article-title>
<source><![CDATA[FASEB J]]></source>
<year>2007</year>
<month> F</month>
<day>eb</day>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>356-65</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teles]]></surname>
<given-names><![CDATA[RMB]]></given-names>
</name>
<name>
<surname><![CDATA[Teles]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Amadeu]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Moura]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Mendonça-Lima]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High matrix metalloproteinase production correlates with immune activation and leukocyte migration in leprosy reactional lesions]]></article-title>
<source><![CDATA[Infect Imunn]]></source>
<year>2010</year>
<month> M</month>
<day>ar</day>
<volume>78</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1012-21</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fayyazi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schweyer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eichmeyer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Herms]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hemmerlein]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Radzun]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Expression of IFN-&#947;, coexpression of TNF-&#945; and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare]]></article-title>
<source><![CDATA[Arch Dermatol Res]]></source>
<year>2000</year>
<month> A</month>
<day>ug</day>
<volume>292</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>384-90</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parks]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[López-Boado]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Matrix metalloproteinases as modulators of inflammation and innate immunity]]></article-title>
<source><![CDATA[Nat Rev Immunol]]></source>
<year>2004</year>
<month> A</month>
<day>ug</day>
<volume>4</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>617-29</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nabeshima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shimao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sameshima]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Matrix metalloproteinases in tumor invasion: role for cell migration]]></article-title>
<source><![CDATA[Pathol Int]]></source>
<year>2002</year>
<month> A</month>
<day>pr</day>
<volume>52</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>255-64</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Unemori]]></surname>
<given-names><![CDATA[EN]]></given-names>
</name>
<name>
<surname><![CDATA[Hibbs]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Amento]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1991</year>
<month> N</month>
<day>ov</day>
<volume>88</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1656-62</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quaresma]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
<name>
<surname><![CDATA[Fuzii]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Libonati]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Pagliari]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immunohistochemical evaluation of macrophage activity and its relationship with apoptotic cell death in the polar forms of leprosy]]></article-title>
<source><![CDATA[Microb Pathog]]></source>
<year>2010</year>
<month> O</month>
<day>ct</day>
<volume>49</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>135-40</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Raine]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fanger]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures]]></article-title>
<source><![CDATA[J Histochem Cytochem]]></source>
<year>1981</year>
<month> A</month>
<day>pr</day>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>577-80</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bobrow]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Shaughnessy]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Litt]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Catalyzed reporter deposition, a novel method of signal amplification: application to immunoassays]]></article-title>
<source><![CDATA[J Immunol Methods]]></source>
<year>1989</year>
<month> D</month>
<day>ec</day>
<volume>125</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>279-85</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabello]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Fatores genéticos nas doenças infecciosas e parasitárias]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Coura]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<source><![CDATA[Dinâmica das doenças infecciosas e parasitárias]]></source>
<year>2005</year>
<publisher-loc><![CDATA[Rio de Janeiro ]]></publisher-loc>
<publisher-name><![CDATA[Guanabara Koogan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rambukkana]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zanazzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tapinos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Salzer]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells]]></article-title>
<source><![CDATA[Science]]></source>
<year>2002</year>
<month> M</month>
<day>ay</day>
<volume>296</volume>
<numero>5569</numero>
<issue>5569</issue>
<page-range>927-31</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Fukutomi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Krahenbuhl]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>1993</year>
<month> O</month>
<day>ct</day>
<volume>61</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>4173-81</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vissa]]></surname>
<given-names><![CDATA[VD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Genomic evidence for the retention of the essential mycobacterial cell wall in the otherwise defective Mycobacterium leprae]]></article-title>
<source><![CDATA[Lepr Rev]]></source>
<year>2001</year>
<month> D</month>
<day>ec</day>
<volume>72</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>415-28</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krutzik]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Sharfstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2005</year>
<month> J</month>
<day>un</day>
<volume>11</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>653-60</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leseleuc]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Van Thuc]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Thai]]></surname>
<given-names><![CDATA[VH]]></given-names>
</name>
<name>
<surname><![CDATA[Huong]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
<name>
<surname><![CDATA[Ba]]></surname>
<given-names><![CDATA[NN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Genetic and functional analysis of common MRC1 exon 7 polymorphisms in leprosy susceptibility]]></article-title>
<source><![CDATA[Hum Genet]]></source>
<year>2010</year>
<month> M</month>
<day>ar</day>
<volume>127</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>337-48</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Lint]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Libert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation]]></article-title>
<source><![CDATA[J Leukoc Bio]]></source>
<year>2007</year>
<month> D</month>
<day>ec</day>
<volume>82</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1375-81</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takeichi]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Okamoto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tsurumachi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cytokine regulation on the synthesis of nitric oxide in vivo by chronically infected human polymorphonuclear leucocytes]]></article-title>
<source><![CDATA[Immunology]]></source>
<year>1998</year>
<month> F</month>
<day>eb</day>
<volume>93</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>275-80</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Suffys]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Vanderborght]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Moraes]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Vieira]]></surname>
<given-names><![CDATA[LMM]]></given-names>
</name>
<name>
<surname><![CDATA[Cabello]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Role of tumor necrosis factor-&#945; and interleukin-10 promoter gene polymorphisms in leprosy]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2002</year>
<month> D</month>
<day>ec</day>
<volume>186</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1687-91</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarno]]></surname>
<given-names><![CDATA[EN]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Jardim]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Suffys]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Nery]]></surname>
<given-names><![CDATA[JAC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pathogenesis of nerve damage in leprosy: genetic polymorphism regulates the production of TNF alpha]]></article-title>
<source><![CDATA[Lepr Rev]]></source>
<year>2000</year>
<month> D</month>
<day>ec</day>
<volume>71</volume>
<page-range>154-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Litle]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Khanolkar-Young]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Coulthart]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suneetha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lockwood]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12 and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>2001</year>
<month> M</month>
<day>ay</day>
<volume>69</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>3413-7</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goulart]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Penna]]></surname>
<given-names><![CDATA[GO]]></given-names>
</name>
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Imunopatologia da hanseniase: a complexidade da resposta imune do hospedeiro ao Mycobacterium leprae]]></article-title>
<source><![CDATA[Rev Soc Bras Med Trop]]></source>
<year>2002</year>
<month> j</month>
<day>ul</day>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>365-75</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kahawita]]></surname>
<given-names><![CDATA[IP]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Lockwood]]></surname>
<given-names><![CDATA[DNJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Leprosy type 1 reactions and erythema nodosum leprosum]]></article-title>
<source><![CDATA[An Bras Dermatol]]></source>
<year>2008</year>
<month> J</month>
<day>an</day>
<volume>83</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-82</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Modlin]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Melancon-Kaplan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[SMM]]></given-names>
</name>
<name>
<surname><![CDATA[Pirmez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kino]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Convit]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Learning from lesions: patterns of tissue inflammation in leprosy]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>1988</year>
<month> F</month>
<day>eb</day>
<volume>85</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1213-7</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pena]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Geluk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Van Der Ploeg-Van Schip]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Franken]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Truman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cytokine responses to Mycobacterium leprae unique proteins differentiate between Mycobacterium leprae infected and naive armadillos]]></article-title>
<source><![CDATA[Lepr Rev]]></source>
<year>2011</year>
<month> D</month>
<day>ec</day>
<volume>82</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>422-31</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Andrigueti]]></surname>
<given-names><![CDATA[FV]]></given-names>
</name>
<name>
<surname><![CDATA[Reis Neto]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Pinheiro]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lepromatous leprosy associated with the use of anti-TNF a therapy: case report]]></article-title>
<source><![CDATA[Rev Bras Reumatol]]></source>
<year>2010</year>
<month> M</month>
<day>ay</day>
<volume>50</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>333-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Teles]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Brandão Teles]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Schwann cells producing matrix metalloproteinases under Mycobacterium leprae stimulation may play a role in the outcome of leprous neuropathy]]></article-title>
<source><![CDATA[J Neuropathol Exp Neurol]]></source>
<year>2010</year>
<month> J</month>
<day>an</day>
<volume>69</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-39</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steenport]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[KMF]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Barnhard]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Dannenberg]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Falcone]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-&#945; and cyclooxygenase-2]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2009</year>
<month> D</month>
<day>ec</day>
<volume>183</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>8119-27</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Neves]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sales]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Sarno]]></surname>
<given-names><![CDATA[EN]]></given-names>
</name>
<name>
<surname><![CDATA[Sampaio]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumor necrosis factor-&#945;]]></article-title>
<source><![CDATA[Immunology]]></source>
<year>2003</year>
<month> M</month>
<day>ay</day>
<volume>109</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>156-64</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Scheller]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Marletta]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Seguin]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Klotz]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Slayter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens]]></article-title>
<source><![CDATA[Immunol Lett]]></source>
<year>1994</year>
<month> D</month>
<day>ec</day>
<volume>43</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>87-94</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Chanock]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Flanders]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transforming growth factor beta isoforms in tuberculoid and leprometous leprosy: immunohistochemical studies]]></article-title>
<source><![CDATA[Cell Vision]]></source>
<year>1995</year>
<volume>2</volume>
<page-range>363</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiszewski]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Becerril]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Baquera]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Pando]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Expression of transforming growth fator-&#946; isoforms and their receptors in lepromatous and tuberculoid leprosy]]></article-title>
<source><![CDATA[Scand J Immunol]]></source>
<year>2003</year>
<month> M</month>
<day>ar</day>
<volume>57</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>279-85</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goulart]]></surname>
<given-names><![CDATA[IMB]]></given-names>
</name>
<name>
<surname><![CDATA[Figueiredo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Coimbra]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Foss]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Detection of transforming growth factor-&#946;1 in dermal lesions of different clinical forms of leprosy]]></article-title>
<source><![CDATA[Am J Pathol]]></source>
<year>1996</year>
<month> M</month>
<day>ar</day>
<volume>148</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>911-7</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goulart]]></surname>
<given-names><![CDATA[IMB]]></given-names>
</name>
<name>
<surname><![CDATA[Mineo]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Foss]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Production of transforming growth factor-beta 1 (TGF-&#946;1) by blood monocytes from patients with different clinical forms of leprosy]]></article-title>
<source><![CDATA[Clinical and Experimental Immunology]]></source>
<year>2000</year>
<month> D</month>
<day>ec</day>
<volume>122</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>330-4</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCartney-Francis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mizel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wahl]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wahl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[TGF-&#946; regulates production of growth factors and TGF-&#946; by human peripheral blood monocytes]]></article-title>
<source><![CDATA[Growth Factors]]></source>
<year>1990</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-35</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khanolkar-Young]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Snowdon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lockwood]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immunocytochemical localization of inducible nitric oxide synthase and transforming growth factor-beta (TGF-&#946;) in leprosy lesions]]></article-title>
<source><![CDATA[Clin Exp Immunol]]></source>
<year>1998</year>
<month> S</month>
<day>ep</day>
<volume>113</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>438-42</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venturini]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Boderline leprosy: in situ and cytokine profile in supernatant of mononuclear cell culture]]></article-title>
<source><![CDATA[J Venom Anim Toxins Incl Trop Dis]]></source>
<year>2009</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>366</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Job]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Krahenbuhl]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Role of inducible nitric oxide synthase inresistance to Mycobacterium leprae in mice]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>2000</year>
<month> S</month>
<day>ep</day>
<volume>68</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>5462-5</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petito]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Amadeu]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Pascarelli]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jardim]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Vital]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transforming growth factor-&#946;1 may be a key mediator of the fibrogenic properties of neural cells in leprosy]]></article-title>
<source><![CDATA[J Neuropathol Exp Neurol]]></source>
<year>2013</year>
<month> A</month>
<day>pr</day>
<volume>72</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>351-66</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moura]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Mattos]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Amadeu]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Sales]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitz]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[CD163 favors Mycobacterium leprae survival and persistence by promoting anti-inflammatory pathways in lepromatous macrophages]]></article-title>
<source><![CDATA[Eur J Immunol]]></source>
<year>2012</year>
<month> N</month>
<day>ov</day>
<volume>42</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2925-36</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Noh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tensile stimuli increase nerve growth factor in human dermal fibroblasts independent of tension-induced TGF&#946; production]]></article-title>
<source><![CDATA[Exp Dermatol]]></source>
<year>2013</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>72-4</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quaresma]]></surname>
<given-names><![CDATA[JAS]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[FAC]]></given-names>
</name>
<name>
<surname><![CDATA[Aarao]]></surname>
<given-names><![CDATA[TLS]]></given-names>
</name>
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[LPMA]]></given-names>
</name>
<name>
<surname><![CDATA[Magno]]></surname>
<given-names><![CDATA[IMN]]></given-names>
</name>
<name>
<surname><![CDATA[Fuzii]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transforming growth factor &#946; and apoptosis in leprosy skin lesions: possible relationship with the control of the tissue immune response in the Mycobacterium leprae infection]]></article-title>
<source><![CDATA[Microbes Infect]]></source>
<year>2012</year>
<month> A</month>
<day>ug</day>
<volume>14</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>696-701</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Patil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cianci]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Howe]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transforming growth factor &#946; induces caspase 3-independent cleavage of &#945;ll-spectrin (&#945;-fodrin) coincident with apoptosis]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>1999</year>
<month> A</month>
<day>ug</day>
<volume>274</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>23256-62</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Sampaio]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Aarestrup]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Teles]]></surname>
<given-names><![CDATA[RMB]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cytokines and Mycobacterium leprae induce apoptosis in human Schwann]]></article-title>
<source><![CDATA[J Neuropathol Exp Neurol]]></source>
<year>2005</year>
<month> O</month>
<day>ct</day>
<volume>64</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>882-90</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
